Safe selective destruction of cells via their internal chemistry, not surface markers, via uptake of lipid-encapsulated programmable suicide gene arrangements. With the right program and a distinctive chemistry to target in the unwanted cell population, this flexible technology has next to no side-effects, and enables rapid development of therapies such as: 1) senescent cell clearance with resorting to chemotherapeut…
Ask HN: What is the most exciting development in your field right now?
131–140 of 436 posts
Re: Ask HN: What is the most exciting development in your field right now?
#132Re: Ask HN: What is the most exciting development in your field right now?
#133Earlier quoted context omitted.
That depends on your background and your goals. How much do you know about modern testing, abstract interpretation, SAT/SMT solving? In any case, as of Feb 2017, a lot of this technology is not yet economical for non-safety critical mainstream programming. Peter O'Hearn's talk at the Turing Institute https://www.youtube.com/watch?v=lcVx3g3SmmY might be of interest.
Very little on abstract interpretation and SAT/SMT solving. I'm effectively starting from 0. I'll go through the talk, thanks! Why isn't it economical yet?
There are some ways in which these tools are not economical. There is currently a big gap. On one side of the gap, you have SMT solvers, which have encoded in them decades of institutional knowledge about generating solutions to formula. An SMT solver is filled with tons of "strategies" and "tactics" which are also known has "heuristics" and "hacks" to everyone else. It applies those heuristics, and a few core algorithms, to formula to automatically come up with a solution. This means that the behavior is somewhat unpredictable, sometimes you can have a formula with 60,000 free variables solved in under half a second, sometimes you can have a formula with 10 that takes an hour.
It sucks when that's in your type system, because then your compilation speeds become variable. Additionally, it's difficult to debug why compiling something would be slow (and by slow, I mean sometimes it will "time out" because otherwise it would run forever) because you have to trace through your programming language's variables into the solvers variables. If a solver can say "no, this definitely isn't safe" most tools are smart enough to pull the reasoning for "definitively not safe" out into a path through the program that the programmer can study.
On the other end of the spectrum are tools like coq and why3. They do very little automatically and require you, the programmer, to specify in painstaking detail why your program is okay. For an example of what I mean by "painstaking" the theorem prover coq could say to you "okay, I know that x = y, and that x and y are natural numbers, but what I don't know is if y = x." You have to tell coq what axiom, from already established axioms, will show that x = y implies y = x.
Surely there's room for some compromise, right? Well, this is an active area of research. I am working on projects that try to strike a balance between these two design points, as are many others, but unlike the GP I don't think there's anything to be that excited about yet.
There's a lot of problems with existing work and applying it to the real world. Tools that reason about C programs in coq have a very mature set of libraries/theorems to reason about memory and integer arithmetic but the libraries they use to turn C code into coq data structures can't deal with C code constructs like "switch." Tools that do verification at the SMT level are frequently totally new languages, with limited/no interoperability with existing libraries, and selling those in the real world is hard.
It's unlikely that any of this will change in the near term because the community of people that care enough about their software reliability is very small and modestly funded. Additionally, making usable developer tools is an orthogonal skill from doing original research, and as a researcher, I both am not rewarded for making usable developer tools, and think that making usable developer tools is much, much harder than doing original research.
Re: Ask HN: What is the most exciting development in your field right now?
#134Unicef open sourcing RapidPro ( https://community.rapidpro.io/about-rapidpro/ )
Re: Ask HN: What is the most exciting development in your field right now?
#135Field: embedded software. To me RISC-V is the most exciting thing for the next few years. The performance appears to be awesome, and free CPU IP will allow more varieties of specialized low-cost chips for specific use cases. It should also have a positive effect on development environments by encouraging wider use of free toolchains.
I'm also doing embedded work, but I don't really see - or expect - performance from the RISC-V cores above similar CPU designs that consume about the same area/gate-equivalents; did I miss some recent results? Of course, freely-available and well-supported CPU IP can be very cool!
A significant hunk of a Cortex-M die is the ARM licensing fee. If we can drop that? That would be an order of magnitude of savings on my BOM.
Re: Ask HN: What is the most exciting development in your field right now?
#136Container orchestrators becoming mainstream is something I'm very excited about. Tools like DC/OS, Nomad, Kubernetes, Docker Swarm Mode, Triton, Rancher make it so much easier to have fast development cycles. Last week I went from idea, to concept, to deployed in production in a single day. And it is automatically kept available, restarted if it fails, traffic is routed correctly, other services can discover it, the…
Re: Ask HN: What is the most exciting development in your field right now?
#137I'm entering radiology residency, and I'm very pro-automation / machine learning. There's a contentious debate in the field about whether radiologists will be replaced: https://forums.studentdoctor.net/threads/will-ai-replace-rad... HackerNews is very developer-focused. If you guys saw what a radiologist does on a 9-5 basis you'd be amazed it hasn't already been automated. Sitting behind a computer, looking at images…
Have any of the methods made radiologists more efficient? If you were to imagine a system that made a radiologist 10x more efficient what would it look like?
There are three areas that take a lot of time that radiologist would like to see automated:
1. Counting lung nodules. 2. Working mammography CAD. 3. Automated bone-age determination.
Those are the hot three topics for machine learning. Personally, I think that a normal vs. non-normal classifier for CXRs would be more interesting because you could have a completely generated note for normal reads, and radiologists could just quickly look at the image without writing/dictating anything. Of note, hospitals and radiology departments typically lose money on X-ray reads because the reimbursement is $7-$20 (compared to $100+ for MR/CT). So if you could halve the read time, they might become profitable again.
Edit: In terms of 10x, what you'd want is a system that would automatically make the reads (i.e. radiologist report), and a very efficient way for radiologist to verify what is written. It's hard to make a pathologic read, but since roughly 50% of reads are normal, you could start with normal reports.
Re: Ask HN: What is the most exciting development in your field right now?
#138Amazon Polly wrt text-to-speech (much cheaper than Ivona and maybe better over the long-term)
Re: Ask HN: What is the most exciting development in your field right now?
#139Earlier quoted context omitted.
I've been interviewing junior/intermediate frontend candidates for the past few months now. 90% don't use any test tools, and their biggest complaint is their current employer forcing a new framework/library for the sake of being bleeding edge. While interesting to them, it turns out most of them really just want to see what they can do with vanilla JS.
Why you expect that junior developer (someone with very little or no development experience) will use a test tool or any other development technique? I expect that junior developer in software field should be able to program only.
That is very often the case. It needs to change. Testing is a part of software development, and anyone who writes software should be aware of it. I feel the same way about documentation. And requirements. You can't write good software without knowledge of the processes that surround development. It isn't enough just to be able to write great code.
Re: Ask HN: What is the most exciting development in your field right now?
#140Safe selective destruction of cells via their internal chemistry, not surface markers, via uptake of lipid-encapsulated programmable suicide gene arrangements. With the right program and a distinctive chemistry to target in the unwanted cell population, this flexible technology has next to no side-effects, and enables rapid development of therapies such as: 1) senescent cell clearance with resorting to chemotherapeut…
How does the targeting work , and is it only inside the cell or also outside of it ?
----------
"Our approach is quite different from most other attempts to clear these cells. We have two components to our potential therapy. First, there is a gene sequence consisting of a promoter that is active in the cells we want to kill and a suicide gene that encodes a protein that triggers apoptosis. This gene sequence can be simple, like the one that kills p16-expressing cells, or more complicated, for example, incorporating logic to make it more cell type specific. The second component is a unique liposomal vector that is capable of transporting our gene sequence into virtually any cell in the body. This vector is unique in that it both very efficient, and appears to be very safe even at extremely high doses."
"There's a subtle but profound distinction between our approach and others. The targeting of the cells is done with the gene sequence, not the vector. The liposomal vector doesn't have any preference for the target cells. It delivers the gene sequence to both healthy and targeted cells. We don't target based on surface markers or other external phenotypic features. We like to say "we kill cells based on what they are thinking, not based on surface markers." So if the promoter used in our gene sequence (say, p16) is active in any given cell at the time of treatment, the next part of our gene sequence - the suicide gene - will be transcribed and drive the cell to apoptosis. However, if p16 isn't active in a given cell, then nothing happens, and shortly afterwards the gene sequence we delivered would simply be degraded by the body. This behavior allows our therapy to be highly specific and importantly, transient. Since we don't use a virus to deliver our gene sequence, and our liposomal vector isn't immunogenic, our hope is that we should be able to use it multiple times in the same patient."